4.7 Article

Early versus late oseltamivir treatment in severely ill patients with 2009 pandemic influenza A (H1N1): speed is life

期刊

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
卷 66, 期 5, 页码 959-963

出版社

OXFORD UNIV PRESS
DOI: 10.1093/jac/dkr090

关键词

antivirals; outcome; virus; critical care; therapy

资金

  1. Astellas
  2. Pfizer
  3. GSK
  4. Roche

向作者/读者索取更多资源

The need for early antimicrobial therapy is well established for life-threatening bacterial and fungal infections including meningitis and sepsis/septic shock. However, a link between the outcome of serious viral infections and delays in antiviral therapy is not as well recognized. Recently, with the occurrence of the influenza A/H1N1 pandemic of 2009, a large body of data regarding this issue has become available. Studies analysing data from this pandemic have consistently shown that delays in initiation of antiviral therapy following symptom onset are significantly associated with disease severity and death. Optimal survival and minimal disease severity appear to result when antivirals are started as soon as possible after symptom onset.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据